Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?

Margulis, Vitaly

Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? [electronic resource] - European urology Sep 2008 - 489-92 p. digital

Publication Type: Editorial

0302-2838

10.1016/j.eururo.2007.12.041 doi


Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Carcinoma, Renal Cell--pathology
Clinical Trials as Topic
Combined Modality Therapy
Humans
Indoles--therapeutic use
Interferon-alpha--therapeutic use
Kidney Neoplasms--pathology
Nephrectomy--methods
Protein Kinases--therapeutic use
Pyrazoles--therapeutic use
Pyrimidines--therapeutic use
Pyrroles--therapeutic use
Sunitinib
Survival Analysis
TOR Serine-Threonine Kinases
Vascular Endothelial Growth Factor A--antagonists & inhibitors